Detalhe da pesquisa
1.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Lancet Oncol
; 24(3): 213-227, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36796394
2.
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 650-658, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35421369
3.
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis.
Br J Cancer
; 126(1): 34-41, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671131
4.
Long-term outcomes of image-guided ablation and laparoscopic partial nephrectomy for T1 renal cell carcinoma.
Eur Radiol
; 32(9): 5811-5820, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35384457
5.
Irreversible electroporation (IRE) in renal cell carcinoma (RCC): a mid-term clinical experience.
Eur Radiol
; 31(10): 7491-7499, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33825033
6.
Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion.
Br J Cancer
; 123(1): 137-147, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32390008
7.
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
BMC Cancer
; 19(1): 1102, 2019 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727024
8.
(-)-Englerin A-evoked Cytotoxicity Is Mediated by Na+ Influx and Counteracted by Na+/K+-ATPase.
J Biol Chem
; 292(2): 723-731, 2017 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27875305
9.
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
J Pathol
; 241(3): 362-374, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27859259
10.
Transient receptor potential canonical 4 and 5 proteins as targets in cancer therapeutics.
Eur Biophys J
; 45(7): 611-620, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27289383
11.
Ureteric Injury after Image-Guided Ablation of Renal Cell Cancer with Irreversible Electroporation.
J Vasc Interv Radiol
; 32(2): 322-324, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33293220
12.
(-)-Englerinâ A is a potent and selective activator of TRPC4 and TRPC5 calcium channels.
Angew Chem Int Ed Engl
; 54(12): 3787-91, 2015 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25707820
13.
Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells.
J Biol Chem
; 288(11): 7467-7480, 2013 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23341459
14.
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.
Angiogenesis
; 17(3): 471-94, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24482243
15.
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).
J Clin Oncol
; 42(3): 312-323, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37931206
16.
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Small Renal Cell Carcinomas after Image-Guided Cryoablation or Radio-Frequency Ablation.
Cancers (Basel)
; 15(7)2023 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37046847
17.
REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers.
Contemp Clin Trials
; 124: 107030, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36519749
18.
Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma.
Clin Cancer Res
; 29(7): 1220-1231, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815791
19.
Renal cancer biomarkers: the promise of personalized care.
BMC Med
; 10: 112, 2012 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-23016578
20.
A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial.
Clin Genitourin Cancer
; 20(5): 473-481, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35803859